» Articles » PMID: 18727647

The Importance of Placebo in Headache Research

Overview
Journal Cephalalgia
Specialties Neurology
Psychiatry
Date 2008 Aug 30
PMID 18727647
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

The best way to appreciate the efficacy of drug and behavioural therapy in the acute and prophylactic treatment of headache is to perform placebo-controlled randomized trials. In order to plan and conduct these studies in the most appropriate way, it is desirable to know which factors influence the placebo response. This paper reviews factors which influence the placebo response in clinical trials, such as expectation, blinding, route of application of drugs and age, gender and geographical distribution. Response rates of placebo in the treatment of acute headache episodes are higher than in headache prophylaxis. Invasive procedures such as injections have a higher placebo response compared with oral drugs. Variables known to influence the placebo response have to be taken into consideration to calculate properly the power of planned randomized trials.

Citing Articles

Translation of Multidimensional Health Locus of Control Scales, Form C in Patients with Headache.

Bartsch L, Fiebig N, Strauss S, Angermaier A, Smith C, Reuter U J Clin Med. 2024; 13(14).

PMID: 39064279 PMC: 11278222. DOI: 10.3390/jcm13144239.


Celecoxib Decreases the Need for Rescue Analgesics after Total Knee Arthroplasty: A Meta-Analysis.

Gomez-Sanchez E, Hernandez-Gomez A, Guzman-Flores J, Alonso-Castro A, Serafin-Higuera N, Balderas-Pena L Clin Pract. 2024; 14(2):461-472.

PMID: 38525714 PMC: 10961807. DOI: 10.3390/clinpract14020035.


Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study.

Overeem L, Peikert A, Hofacker M, Kamm K, Ruscheweyh R, Gendolla A Cephalalgia. 2021; 42(4-5):291-301.

PMID: 34644203 PMC: 8988456. DOI: 10.1177/03331024211048765.


Temporary resolution of hemicrania continua following ipsilateral ear piercing.

Bryson A BMJ Neurol Open. 2021; 3(2):e000193.

PMID: 34632387 PMC: 8477251. DOI: 10.1136/bmjno-2021-000193.


Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials.

Tepper S, Ashina M, Reuter U, Hallstrom Y, Broessner G, Bonner J J Headache Pain. 2021; 22(1):81.

PMID: 34301173 PMC: 8299690. DOI: 10.1186/s10194-021-01292-w.